tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
KalVista Highlights Strong EKTERLY Launch and Global Uptake
PremiumCompany AnnouncementsKalVista Highlights Strong EKTERLY Launch and Global Uptake
28d ago
KalVista price target raised to $32 from $28 at Needham
Premium
The Fly
KalVista price target raised to $32 from $28 at Needham
30d ago
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
Premium
Ratings
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
30d ago
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
PremiumRatingsPositive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
2M ago
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
Premium
Ratings
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
2M ago
KalVista Pharmaceuticals, Inc. (KALV) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
KalVista Pharmaceuticals, Inc. (KALV) Q2 Earnings Cheat Sheet
2M ago
KalVista Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
PremiumRatingsKalVista Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
3M ago
KalVista reports Q3 EPS (92c) vs. (84c) last year
Premium
The Fly
KalVista reports Q3 EPS (92c) vs. (84c) last year
3M ago
Buy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100